Intended for healthcare professionals

Letters Drug firm conflicting interests

If only WHI was done well

BMJ 2010; 340 doi: (Published 17 February 2010) Cite this as: BMJ 2010;340:c591

This article has a correction. Please see:

  1. John C Stevenson, reader in metabolic medicine1,
  2. Howard N Hodis, professor of medicine and preventive medicine2,
  3. James H Pickar, adjunct associate professor of gynaecology3,
  4. Rogerio A Lobo, professor of gynaecology3
  1. 1National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, London SW3 6NP
  2. 2Atherosclerosis Research Unit, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
  3. 3Obstetrics and Gynecology, Columbia University Medical Center, New York, NY 10032, USA
  1. j.stevenson{at}

    Barrington claims that the women’s health initiative (WHI) trial had impeccable standards.1 We recently highlighted some of its shortcomings relating to hormone replacement therapy (HRT).2

    The data and safety monitoring board used a global index of health which was modified on three occasions, including once after formal monitoring had started. Although the oestrogen-progestogen arm of the studies was stopped after a designated safety boundary was breached, the oestrogen alone arm was stopped by staff of the National Heart, Lung and Blood Institute …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription